MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 15.8 KB

The release as fetched from its publisher. macrogenics.com ↗